Werewolf Therapeutics develops conditionally activated therapeutics engineered to stimulate the immune system for cancer and other immune-mediated conditions. News about HOWL centers on the company’s PREDATOR platform, INDUKINE molecules, INDUCER T cell engager work, and programs such as WTX-124 and WTX-330.
Recurring updates include clinical and preclinical data presentations, FDA regulatory designations, operating and financial results, program licensing or asset-rights activity, capital-structure actions, shareholder voting matters, and corporate-strategy updates tied to the company’s oncology-focused development pipeline.
Werewolf Therapeutics (Nasdaq: HOWL) announced significant advancements in its clinical trials and financial position. The company is preparing to release initial clinical data for its IL-2 INDUKINE WTX-124 monotherapy in Q4 2023, while the first patient has been dosed in the IL-12 INDUKINE WTX-330 trial. Furthermore, it nominated WTX-712 for preclinical development. The financial update shows a cash position of $129.3 million, with guidance extended to cover operations through Q4 2024. Collaboration revenue rose to $7.3 million in Q4 2022, a notable increase from 2021, amidst rising expenses primarily related to R&D.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the publication of abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. Key presentations include:
- Abstract 1829: Generation of IL-21 INDUKINE™ molecules for cancer treatment on April 17, 9:00 a.m. - 12:30 p.m.
- Abstract CT133: Phase 1/1b study of WTX-124, April 17, 1:30 p.m. - 5:00 p.m.
- Abstract CT254: First-in-human study of WTX-330 on April 18, 1:30 p.m. - 5:00 p.m.
Werewolf is focused on conditionally activated therapeutics to enhance the immune response against cancer.
Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The abstract, numbered 1829, details the generation of IL-21 INDUKINE™ molecules aimed at activating the immune system while minimizing side effects. The presentation will occur on April 17 from 9:00 a.m. to 12:30 p.m. at Poster Section 24, Board Number 1. The company utilizes its proprietary PREDATOR™ platform to develop conditionally activated therapeutics targeting solid tumors, including its lead candidates, WTX-124 and WTX-330.
Werewolf Therapeutics has initiated a Phase 1 clinical trial for WTX-330, a novel Interleukin-12 (IL-12) therapy designed for the treatment of advanced solid tumors and Non-Hodgkin lymphoma. This trial marks the second INDUKINE molecule to enter clinical evaluation from their PREDATOR protein engineering platform. Dosing the first patient highlights Werewolf's commitment to advancing cancer therapies targeting hard-to-treat tumors. WTX-330 aims to minimize off-tumor toxicities while delivering potent treatment directly to the tumor microenvironment, potentially maximizing clinical benefits.
Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced that Randi Isaacs, M.D., its Chief Medical Officer, will present at the SVB Securities Global Biopharma Conference. The virtual presentation is scheduled for February 16, 2023, at 8:40 AM ET, during the conference which runs from February 14-16. This event highlights the company's innovative PREDATOR™ platform, designed to stimulate the immune system while minimizing peripheral activity. Werewolf's leading candidates, WTX-124 and WTX-330, are conditionally activated molecules aimed at treating various solid tumors. A link to the live webcast and archived presentation will be available following the event.
Werewolf Therapeutics presented preclinical data on mWTX-330, an innovative IL-12 therapy, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer. The findings suggest mWTX-330 promotes significant anti-tumor activity and immune cell activation in the tumor microenvironment. Additionally, the FDA recently cleared the IND application for WTX-330, paving the way for clinical trials. This therapy aims to treat advanced solid tumors and lymphoma, potentially offering improved efficacy and safety over existing IL-12 therapies.
Werewolf Therapeutics (HOWL) announced significant advancements in its clinical pipeline, including the first patient dosed in a Phase 1/1b trial for WTX-124, targeting advanced solid tumors, with preliminary data expected in Q4 2023. The FDA granted IND clearance for WTX-330, aimed at treating relapsed/refractory tumors. The company reported a cash balance of $140.5 million, sufficient to fund operations through at least Q2 2024, alongside $5 million in collaboration revenue. Net loss for Q3 2022 was reduced to $11.9 million from $13.8 million YoY.
Werewolf Therapeutics (Nasdaq: HOWL) will present preclinical data on its IL-12 INDUKINE molecule, mWTX-330, at the Society for Immunotherapy of Cancer's 37th Annual Meeting on November 11, 2022. This research focuses on tumor-infiltrating lymphocytes and the tumor microenvironment in murine models. Additionally, the management team is set to engage in several investor conferences, including the Jefferies London Healthcare Conference on November 15 and the Piper Sandler Conference on November 29. These events aim to enhance investor relations and share insights into Werewolf's innovative cancer therapies.
Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.
Werewolf Therapeutics announced the first patient has been dosed in the Phase 1/1b trial for WTX-124, its leading INDUKINE™ molecule targeting IL-2 for treating solid tumors. This multi-center, open-label trial will evaluate WTX-124 alone and with KEYTRUDA® in patients with advanced solid tumors who have not responded to standard care. The innovative design aims to minimize toxicities associated with conventional IL-2 therapy while enhancing anti-tumor activity in the tumor microenvironment. This pivotal milestone reflects Werewolf's commitment to advancing its oncology pipeline.